tiprankstipranks
Rapt Therapeutics reports Q3 EPS (47c), consensus (56c)
PremiumThe FlyRapt Therapeutics reports Q3 EPS (47c), consensus (56c)
8d ago
Rapt Therapeutics price target lowered to $4 from $17 at Wells Fargo
Premium
The Fly
Rapt Therapeutics price target lowered to $4 from $17 at Wells Fargo
8d ago
Rapt Therapeutics downgraded to Neutral from Overweight at Piper Sandler
Premium
The Fly
Rapt Therapeutics downgraded to Neutral from Overweight at Piper Sandler
9d ago
Rapt Therapeutics price target lowered to $17 from $24 at Wells Fargo
PremiumThe FlyRapt Therapeutics price target lowered to $17 from $24 at Wells Fargo
3M ago
Rapt Therapeutics says workforce reduction affected 47 people
Premium
The Fly
Rapt Therapeutics says workforce reduction affected 47 people
3M ago
Rapt Therapeutics reports Q2 EPS (71c), consensus (72c)
Premium
The Fly
Rapt Therapeutics reports Q2 EPS (71c), consensus (72c)
3M ago
Rapt Therapeutics downgraded to Equal Weight from Overweight at Barclays
PremiumThe FlyRapt Therapeutics downgraded to Equal Weight from Overweight at Barclays
6M ago
Rapt Therapeutics downgraded to Neutral from Buy at Guggenheim
Premium
The Fly
Rapt Therapeutics downgraded to Neutral from Buy at Guggenheim
6M ago
RAPT Therapeutics trading resumes
Premium
The Fly
RAPT Therapeutics trading resumes
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100